Introduction
Fiber Optics for dissolution testing has been beyond the prototype stage for over five years now. It is a labor saving and efficient way to analyze and sample dissolution testing procedures. There still appears to be some resistance by companies to fully embrace this technology. One aspect of this article will be to explore a regulatory perspective on this technology. Decisions on whether to use or purchase such technology may be guided by assessing certain aspects of the equipment. A checklist will be provided to assist in this effort. Once a company has decided to use this new technology for products then how would the proper validation be performed will be explored. The method for showing equivalence to the more traditional sampling/analyzing method will be described. There will be a discussion of the utility of fiber optics in newer dosage form types and special testing.
Regulatory Update
The perception that USP or FDA may not be in favor of new technology is not an accurate assessment. We have heard that FDA and USP are not in favor of a proliferation of new equipment and this is a point easily understood. However, this does not preclude or should be intended to discourage improvements in efficiency or the science provided in new technology. There are some indications that the regulators do not discourage this fiber optic technology along with other new technologies. At USP for instance, there was a stimuli article published in Pharmacopeial Forum (PF) (1) where a new dissolution informational general chapter was put forth. In the abstract of that article, one of the purposes of the new chapter would be to give guidance to the analyst on validation and use of new technology and equipment. Under the Method Validation section in the discussion of spectrophotometric analysis, the statement is made that "Fiber optics as a determinative method, with proper validation, is an option". This article in PF is now the foundation of a proposal for a new general chapter in USP.
In General Chapter <851> Spectrophotometry and Light-Scattering, there has been discussions centering on highlighting the fiber optic technology in some way. This may appear in future revisions to this chapter.
In USP General Notices (2), under the section TESTS AND ASSAYS in the Apparatus discussion, it states that "Where an instrument for physical measurement, such as a spectrophotometer, is specified in a test or assay by its distinctive name, another instrument of equivalent or greater sensitivity or accuracy may be used."The Notices go on to say,"Items capable of equal or better performance may be used if these characteristics have been validated' . In the Procedures, there is the following discussion of automated procedures:
Automated procedures employing the same basic chemistry as those assay and test procedures given in the monograph are recognized as being equivalent in their suitability for determining compliance. Conversely, where an automated procedure is given in the monograph, manual procedures employing the same basic chemistry are recognized as being equivalent in their suitability for determining compliance. Compliance may be determined also by the use of alternative methods, chosen for advantages in accuracy, sensitivity, precision, selectivity, or adaptability to automation or computerized data reduction or in other special circumstances. Such alternative automated procedures or methods shall be validated. However, Pharmacopeial standards and procedures are interrelated; therefore, where a difference appears or in the event of dispute, only the result obtained by the procedure given in this Pharmacopeia is conclusive.
This discussion clearly paves the way for new technology as long as it is coupled with the proper validation. The FDA, in 21 CFR Part 11, the area of computer generated data is under scrutiny for accuracy and audit trails. Obviously, since there is a high degree of computerized data collection, this aspect needs to be considered when validating the fiber optic system software. Meeting the FDA regudx.doi.org/10.14227/DT100403P33 lations in this area are going a long way to secure FDA approval of the new technology.
The laboratories of both FDA and USP have used fiber optic dissolution testing,a positive indication that the technology is becoming more commonplace and acceptable.
Evaluating the Fiber Optics system
There are several vendors specializing in fiber optic equipment for dissolution testing and we are lucky to have such willing and cooperative vendors when it comes to the nitty gritty of how does the equipment work in your hands or with your product.
If you are serious about purchasing the equipment, and there is management approval, it is suggested that you bring the equipment in-house for a loan. Be sure you use it on several typical formulations and have someone devote full time energy to the evaluation. Some formulators tend to use the same excipients over and over again. If this is the case, be sure those products are used for evaluation. Presented here is a checklist of major equipment parameters to evaluate when examining the various brands. This list is fairly comprehensive, but there may be aspects important to your products and operating procedures that are not covered. Assess the technical support. Is it worthwhile to retrofit to existing equipment?
Validation
The stage of development for your product would determine the level of validation for your fiber optic system. If you are just scouting a formulation you may only need to know the linear range to begin obtaining data. As you become closer to reportable data collection,the validation parameters that are necessary increase. Products in early development would need precision,linearity and range,and recovery (maybe just a fast stir/infinity value would be enough). But most importantly at this stage,the placebo interference or turbidity and light-scattering effects should be determined. It may be that the background correction is adequate,or if the capability exists-second derivative calculations may generate data that is accurate and useable. The background or placebo interference should be kept 2-3% or below. Some labs feel up to 5 % is tolerable. If the interference can not be minimized,the traditional UV or HPLC with filtration may be necessary.
After the placebo interference has been minimized and is shown to be accurate and reportable, the last validation aspect must be considered. That is the manual versus automation (fiber optic) sampling method. This is where the hydrodynamic effect of the fiber optic probe is assessed. One method of performing this comparison could be as follows:
Perform two concurrent runs (using identical sampling time intervals, n = 6) using manual and automated (fiber optic) sampling methods. This is four runs total, two manual and two using the fiber optic system. Typical acceptance criteria are that the difference in the mean value between the dissolution results from the manual run versus fiber optic system run does not exceed an absolute 10% at time points with less than 85% dissolved and does not exceed 5% for those remaining time points above 85%. Acceptance criteria may be product specific, and other statistical tests and limits may be used (1).
Performing a blank run after multiple runs of the highest strength may validate the cleaning procedure of the fiber optic system.
The validation for the final product as it approaches later stages/phases will include ruggedness, robustness, recovery studies, and solution and sample stability.
Documentation
At some point a validation report will be written, either as a part of an NDA or ANDA filing or as early phase documentation. It would be useful to have a special section devoted to the validation of the fiber optic system. The comparison to the manual method would be a critical part of the report. The unique aspects of the fiber optic operation, that is the cleaning of the cells, standard reading or matrix procedure, and the calculations are important. The calculations, especially the background or second derivative formulas, should be clearly explained and validated and in conformance to 21 CFR Part 11.
If there is an established method either in the USP or NDA/ANDA, a new technology such as fiber optics may be validated and used routinely. The new methodology could be filed in the next annual report, which would include the validation report.
Other Products/Uses for Fiber Optic Technology
Transdermal, powder, and intrinsic dissolution will be ideal for fiber optics, as there are no excipients to interfere with the analysis. Products where there are extrusion issues with filtration as modified parenteral products, for example, nanospheres and liposomes, may be analyzed more easily using fiber optics. Other apparatus other than USP Apparatus 1 and 2 could in the future use fiber optic probes. It would be necessary for the probe to go into a well-mixed vessel and to sample at an appropriate place.
Conclusion
There are many advantages to using a fiber optic system versus a conventional sampling and detecting method. The elimination of filtration and sample collection is a huge saving of labor and resources. The analyst should explore this new technology and feel they are within the boundaries of acceptable methodology provided the proper validation occurs. Fiber optics technology will most likely improve and more applications discovered.
A bibliography of many articles published on fiber optics is referenced to assist the analyst in becoming more knowledgeable and better trained to use the technology.
